% | $
Quotes you view appear here for quick access.

Pfizer Inc. Message Board

  • chrt13 chrt13 Nov 8, 2007 11:51 AM Flag

    BIIB revenue breakdown - Q3-07


    67% product sales ($530M)
    30% unconsolidated joint businesses ($234M)
    03% royalties ($25M)

    The product sales breakdown is as follows:

    $455M for Avonex
    $063M for Tysabri
    $012M for all other

    $530M for Q3-07

    There are really only two products comprising product sales - Multiple sclerosis drugs Avonex and Tysabri.

    Most other revenues come from unconsolidated partnerships.

    Consensus estimates out to 2011 indicate earnings per share of $4.20 on the 289 million shares - or about $1.2B. By extension, perhaps $1.35B would be seen in 2012.

    That is less than the $1.5B that I was penciling in for acquisitions and the consensus estimates also could very well be high. PFE can do a lot better than this with $25B.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
33.59+0.19(+0.57%)1:36 PMEDT